153 related articles for article (PubMed ID: 17306791)
1. A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice.
Cyrus T; Yao Y; Ding T; Dogné JM; Praticò D
Eur J Pharmacol; 2007 Apr; 561(1-3):105-11. PubMed ID: 17306791
[TBL] [Abstract][Full Text] [Related]
2. BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase.
Cherdon C; Rolin S; Hanson J; Ooms A; de Leval L; Drion P; Michiels C; Pirotte B; Masereel B; Sakalihassan N; Defraigne JO; Dogné JM
Prostaglandins Other Lipid Mediat; 2011 Apr; 94(3-4):124-32. PubMed ID: 21397034
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism.
Egan KM; Wang M; Fries S; Lucitt MB; Zukas AM; Puré E; Lawson JA; FitzGerald GA
Circulation; 2005 Jan; 111(3):334-42. PubMed ID: 15655126
[TBL] [Abstract][Full Text] [Related]
4. Effect of BM-573 [N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, in a porcine model of acute pulmonary embolism.
Ghuysen A; Lambermont B; Dogné JM; Kolh P; Tchana-Sato V; Morimont P; Magis D; Hanson J; Segers P; D'Orio V
J Pharmacol Exp Ther; 2004 Sep; 310(3):964-72. PubMed ID: 15121765
[TBL] [Abstract][Full Text] [Related]
5. Thromboxane receptor blockade improves the antiatherogenic effect of thromboxane A2 suppression in LDLR KO mice.
Cyrus T; Yao Y; Ding T; Dogné JM; Praticò D
Blood; 2007 Apr; 109(8):3291-6. PubMed ID: 17158227
[TBL] [Abstract][Full Text] [Related]
6. Heparin inhibits the production of matrix metalloproteinase-2 and improves atherosclerosis in LDL receptor-deficient mice.
Guo H; Xu F; Sun A; Liu L; Shi Y
Coron Artery Dis; 2010 Jan; 21(1):39-45. PubMed ID: 19940766
[TBL] [Abstract][Full Text] [Related]
7. Additive anti-atherogenic effect of thromboxane receptor antagonism with 12/15lipoxygenase gene disruption in apolipoprotein E-deficient mice.
Tang L; Ding T; Praticò D
Atherosclerosis; 2008 Aug; 199(2):265-70. PubMed ID: 18206890
[TBL] [Abstract][Full Text] [Related]
8. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis.
Cayatte AJ; Du Y; Oliver-Krasinski J; Lavielle G; Verbeuren TJ; Cohen RA
Arterioscler Thromb Vasc Biol; 2000 Jul; 20(7):1724-8. PubMed ID: 10894809
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
Hanson J; Rolin S; Reynaud D; Qiao N; Kelley LP; Reid HM; Valentin F; Tippins J; Kinsella BT; Masereel B; Pace-Asciak C; Pirotte B; Dogné JM
J Pharmacol Exp Ther; 2005 Apr; 313(1):293-301. PubMed ID: 15626721
[TBL] [Abstract][Full Text] [Related]
10. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice.
Kobayashi T; Tahara Y; Matsumoto M; Iguchi M; Sano H; Murayama T; Arai H; Oida H; Yurugi-Kobayashi T; Yamashita JK; Katagiri H; Majima M; Yokode M; Kita T; Narumiya S
J Clin Invest; 2004 Sep; 114(6):784-94. PubMed ID: 15372102
[TBL] [Abstract][Full Text] [Related]
11. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice.
Nofer JR; Bot M; Brodde M; Taylor PJ; Salm P; Brinkmann V; van Berkel T; Assmann G; Biessen EA
Circulation; 2007 Jan; 115(4):501-8. PubMed ID: 17242282
[TBL] [Abstract][Full Text] [Related]
12. Ticlopidine attenuates progression of atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice.
Jawien J; Csanyi G; Gajda M; Mateuszuk L; Lomnicka M; Korbut R; Chlopicki S
Eur J Pharmacol; 2007 Feb; 556(1-3):129-35. PubMed ID: 17174298
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time.
Dogné JM; Hanson J; de Leval X; Kolh P; Tchana-Sato V; de Leval L; Rolin S; Ghuysen A; Segers P; Lambermont B; Masereel B; Pirotte B
J Pharmacol Exp Ther; 2004 May; 309(2):498-505. PubMed ID: 14742735
[TBL] [Abstract][Full Text] [Related]
14. Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice.
Guo H; Shi Y; Liu L; Sun A; Xu F; Chi J
Arch Med Res; 2009 Jul; 40(5):345-51. PubMed ID: 19766896
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin inhibition decreases progression of advanced atherosclerosis and stabilizes established atherosclerotic plaques.
Suganuma E; Babaev VR; Motojima M; Zuo Y; Ayabe N; Fogo AB; Ichikawa I; Linton MF; Fazio S; Kon V
J Am Soc Nephrol; 2007 Aug; 18(8):2311-9. PubMed ID: 17634441
[TBL] [Abstract][Full Text] [Related]
16. HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice.
van Wanrooij EJ; Happé H; Hauer AD; de Vos P; Imanishi T; Fujiwara H; van Berkel TJ; Kuiper J
Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2642-7. PubMed ID: 16239591
[TBL] [Abstract][Full Text] [Related]
17. Expression of thromboxane synthase, prostacyclin synthase and thromboxane receptor in atherosclerotic lesions: correlation with plaque composition.
Cyrus T; Ding T; Praticò D
Atherosclerosis; 2010 Feb; 208(2):376-81. PubMed ID: 19735918
[TBL] [Abstract][Full Text] [Related]
18. Effects of BM-573 on Endothelial Dependent Relaxation and Increased Blood Pressure at Early Stages of Atherosclerosis.
Romero M; Leon-Gomez E; Lobysheva I; Rath G; Dogné JM; Feron O; Dessy C
PLoS One; 2016; 11(3):e0152579. PubMed ID: 27019366
[TBL] [Abstract][Full Text] [Related]
19. Blockade of scavenger receptor class B type I raises high density lipoprotein cholesterol levels but exacerbates atherosclerotic lesion formation in apolipoprotein E deficient mice.
Kitayama K; Nishizawa T; Abe K; Wakabayashi K; Oda T; Inaba T; Amemiya Y
J Pharm Pharmacol; 2006 Dec; 58(12):1629-38. PubMed ID: 17331327
[TBL] [Abstract][Full Text] [Related]
20. Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice.
Babaev VR; Ishiguro H; Ding L; Yancey PG; Dove DE; Kovacs WJ; Semenkovich CF; Fazio S; Linton MF
Circulation; 2007 Sep; 116(12):1404-12. PubMed ID: 17724261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
